Affibody AB

At Affibody, our mission is to transform the future of healthcare through the development of innovative biotherapeutics! With our Affibody® technology platform, we are designing novel molecules that target diseases with precision, offering new hope to patients with unmet medical needs. Our current focus areas include oncology, autoimmune diseases, and inflammatory conditions. We are developing therapies that specifically target HER2-positive cancers, immune-driven diseases such as asthma, and other complex disorders that conventional treatments struggle to address. The properties of Affibody® molecules allows for more efficacious blocking by using multi-specific constructs, as shown in clinical trials in autoimmune diseases. Together with our partners, we hope to bring life-changing therapies to those who need them most. Find out more about what we do! https://www.affibody.se/ #Biotechnology #Oncology #AutoimmuneDiseases

Today is an important day for protein science, as we celebrate David Baker, Demis Hassabis, and John Jumper, recipients of the 2024 Nobel Prize in Chemistry. At Affibody, we share their passion for protein science and its promise for improving the lives of patients. Their innovative use of AI in unravelling protein complexities has transformed our field and underpins our daily work in the development of next-generation biopharmaceuticals. Here's to future discoveries and advancements in the world of proteins! 🚀

Our Director of Translational Medicine, Nina Eissler, just delivered her talk at the Targeted Radiopharmaceuticals Summit Europe, which we are delighted was well received.   Nina shared insights into Affibody’s work in developing a theranostic pair for molecular imaging and precision medicine, targeting HER2, a key oncogenic driver overexpressed in various solid tumours.    She highlighted how the Affibody PET tracer, tezatabep matraxetan (ABY-025), can identify HER2-positive tumor lesions in their anatomical context, enabling patient stratification for HER2-targeted therapies and providing a window into disease heterogeneity. She also discussed how through advanced protein engineering, the radiotherapeutic candidate ABY-271 has been optimised to achieve a favourable tissue distribution profile. Preclinical studies show that ABY-271 has promising efficacy and a balanced safety profile. Early results from the first-in-human study in breast cancer are expected in 2025. 

We're excited to share that our Director of Translational Medicine, Nina Eissler, will be presenting at the Targeted Radiopharmaceuticals Summit Europe in Amsterdam on December 5th!   At 12:00 pm, Nina will discuss the exciting potential of Affibody molecules as theranostics in molecular imaging and treatment of HER2-expressing cancers. Her presentation, titled "Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2-Expressing Malignancies," will highlight:   ✅ Why image-guided decisions are proving superior to traditional immunohistochemistry for patient selection. ✅ How the PET tracer ABY-025 demonstrates improved patient selection and treatment response prediction. ✅ The development of ABY-271 as a promising candidate for radioligand therapy targeting HER2-expressing malignancies with early results from the first-in-human study in breast cancer expected in 2025.   For those attending the summit, don't miss this session!   Get in touch if you would like to schedule a meeting with Nina: reception@affibody.com

Our innovative Affibody® molecules can be attached to radioactive agents for precise tumor targeting. Once injected, these molecules quickly find and bind to specific surface proteins on cancer cells, where they remain to deliver highly focused radiation. This precision minimizes damage to healthy tissue and helps initiate the body's immune system to detect and kill any remaining cancer cells. This unique mechanism offers potential for combination therapies with immuno-oncology drugs. In collaboration with esteemed academic institutions and GE HealthCare, we are driving progress in oncology with leading candidates ABY-025 and GE-226, PET tracers that enable non-invasive imaging of HER2 expression in cancers like breast and gastric cancer. These tracers help detect HER2 levels and monitor therapy response, expanding treatment options for more patients. Learn more about our pipeline: https://lnkd.in/dukR7hcG #Oncology #Antibodies

Great news for Affibody as well!

It was fantastic to see such an engaged audience at our CSO Fredrik Frejd’s presentation yesterday at #PEGSEurope, who showed interest in learning about the engineering of optimised Affibody-based radiopharmaceuticals.    This event truly brought together experts who appreciate and are committed to addressing the challenge of achieving balanced distribution for optimal efficacy and tolerability.   A big thank you to everyone who attended and for your enthusiasm in our work!

‘Smaller can be better’! Listen to this insightful short interview with our CEO, David Bejker, recorded live from the floor at #BIOEurope with BiotechTV, and learn how Affibody’s unique platform has the potential to generate drug candidates with significant advantages over conventional monoclonal antibodies.    If you’re currently attending BIO Europe and would like to learn more from David in person, please connect via the partnering platform or email david.bejker@affibody.se 🎬 👉 Watch the interview here: https://lnkd.in/gkRBRfMX

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞: BIO-Europe: The CEO of Sweden's Affibody AB on trying to be better than antibodies, moving into the radiopharmaceutical space, and IPO rumors. David Bejker describes how affibody's are meant to compete with monoclonal antibodies, which the company's lead program in IL-17. Plus, entering the clinic in the radiopharma space next year and pouring cold water on IPO talk (for now). Full video: https://lnkd.in/gkRBRfMX BiotechTV's coverage of #BIOEurope is brought to you by Pareto Securities BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

It’s a busy week for the Affibody team next week! Whilst some of us will be at BIO-Europe, our CSO Fredrik Frejd is heading to Barcelona to give a presentation at PEGS Europe 2024, the Protein & Antibody Engineering Summit, on 5-7 November.     Fredrik will be discussing our activities in radiopharma during his talk titled “Development of ABY-271 and the ABY-025 Affibody Theranostic Pair for Patients with HER2-Expressing Disease".   Abstract:  HER2 is an oncogenic driver of several cancers. An affibody molecule specific for HER2 has been developed. Receptor expression levels in metastatic lesions in patients with spread disease can be determined using PET imaging. Tissue distribution profile has been optimised for therapy by protein engineering. Preclinical data show potential for therapeutic effect in combination with trastuzumab. ABY-271 is in preclinical development for molecular radiotherapy of patients with HER2-expressing disease.   When?  🕰️ 9:30am on 6 November   Don’t miss it!   Get in touch if you’d like to meet with us at the conference: https://lnkd.in/ewRpSnUp